Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Anticancer Res. 2019 Nov;39(11):6231-6240. doi: 10.21873/anticanres.13832.
BACKGROUND/AIM: The present study aimed to prospectively examine the usefulness of interferon-gamma (IFN-γ) release (IGR) as a biomarker in non-small-cell lung cancer patients receiving immune checkpoint inhibitor treatment (ICI-Tx).
IGR was measured using enzyme-linked immunosorbent assay at four time points: within 14 days before ICI-Tx (T1), and 8±3 (T2), 22±7 (T3), and 43±7 (T4) days after ICI-Tx.
Twenty-nine patients were divided into three groups based on IFN-γ levels in the IGR-positive control: Group-1 (n=8) with <10 IU/ml at T1, Group-2 (n=12) with a decrease in IFN-γ levels to <10 IU/ml at T3 and/or T4, and Group-3 (n=9) without changes in IFN-γ levels. Early progression and ICI-induced interstitial pneumonitis were frequently observed in Group-1 and Group-2, respectively. Group-3 exhibited more treatment cycles than the other groups. All three groups showed clear differences in clinical outcomes.
IFN-γ levels could be a biomarker for ICI-Tx.
背景/目的：本研究旨在前瞻性评估干扰素-γ（IFN-γ）释放（IGR）作为接受免疫检查点抑制剂治疗（ICI-Tx）的非小细胞肺癌患者的生物标志物的有用性。
IGR 使用酶联免疫吸附测定法在四个时间点进行测量：ICI-Tx 前 14 天内（T1），以及 ICI-Tx 后 8±3 天（T2）、22±7 天（T3）和 43±7 天（T4）。
根据 IGR 阳性对照中 IFN-γ 水平，将 29 名患者分为三组：组 1（n=8）在 T1 时 IFN-γ<10 IU/ml，组 2（n=12）在 T3 和/或 T4 时 IFN-γ 水平下降至<10 IU/ml，组 3（n=9）IFN-γ 水平无变化。分别在组 1 和组 2 中观察到早期进展和 ICI 诱导的间质性肺炎。组 3 的治疗周期比其他组多。三组的临床结局均有明显差异。
IFN-γ 水平可能是 ICI-Tx 的生物标志物。
